

1

2 **Dynamic interactions of influenza viruses in Hong Kong during**
3 **1998-2018**

4

5 Wan Yang^{1*}, Eric H. Y. Lau², Benjamin J. Cowling²

6 *¹Department of Epidemiology, Mailman School of Public Health, Columbia University, New*
7 *York, NY 10032*

8 *²WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public*
9 *Health, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong Special*
10 *Administrative Region, China*

11

12

13 *Correspondence to:

14 Wan Yang

15 Department of Epidemiology

16 Mailman School of Public Health

17 Columbia University

18 722 W 168th Street, Room 514, New York, NY 10032

19 Phone: (212) 305-0421

20 Email: wy2202@columbia.edu

21 **Abstract**

22 Influenza epidemics cause substantial morbidity and mortality every year worldwide.
23 Currently, two influenza A subtypes, A(H1N1) and A(H3N2), and type B viruses co-circulate
24 in humans and infection with one type/subtype could provide cross-protection against the
25 others. However, it remains unclear how such ecologic competition via cross-immunity and
26 antigenic mutations that allow immune escape impact influenza epidemic dynamics at the
27 population level. Here we develop a comprehensive model-inference system and apply it to
28 study the evolutionary and epidemiological dynamics of the three influenza types/subtypes
29 in Hong Kong, a city of global public health significance for influenza epidemic and
30 pandemic control. Utilizing long-term influenza surveillance data since 1998, we are able to
31 estimate the strength of cross-immunity between each virus-pairs, the timing and
32 frequency of punctuated changes in population immunity in response to antigenic
33 mutations in influenza viruses, and key epidemiological parameters over the last 20 years
34 including the 2009 pandemic. We find evidence of cross-immunity in all types/subtypes,
35 with strongest cross-immunity from A(H1N1) against A(H3N2). Our results also suggest
36 that A(H3N2) may undergo antigenic mutations in both summers and winters and thus
37 monitoring the virus in both seasons may be important for vaccine development. Overall,
38 our study reveals intricate epidemiological interactions and underscores the importance of
39 simultaneous monitoring of population immunity, incidence rates, and viral genetic and
40 antigenic changes.

41

42 **Key words:** Influenza; cross-immunity; ecologic competition; seasonality; population
43 susceptibility; punctuated antigenic change

44 **Introduction**

45 Influenza epidemics recur annually in many regions of the world and cause significant
46 morbidity and mortality, leading to 3 to 5 million severe infections and 291,000 to 646,000
47 deaths worldwide each year (1, 2). These recurrent epidemics are a combined outcome of
48 viral antigenic changes, interactions among co-circulating influenza viruses, transmission
49 and host immune response. Influenza viruses undergo continual genetic mutations and
50 punctuated antigenic changes, which allow them to escape prior immunity and cause new
51 epidemics (3-6). In addition, currently two influenza A subtypes, A(H1N1) and A(H3N2),
52 and influenza B co-circulate in humans; and infection of a certain type/subtype can result
53 in partial immunity to influenza strains of the same type/subtype as well as strains across
54 subtypes (7-15) and types (16-18). The latter cross-reactive immunity—termed cross-
55 immunity—leads to epidemiological interactions among influenza viruses that, along with
56 viral antigenic changes, shape influenza phylodynamics and epidemic dynamics (19-31).
57 Improving understanding of interactions among influenza viruses and the resulting impact
58 on epidemic dynamics will thus provide insights to aid public health efforts to mitigate the
59 burden of influenza.

60
61 As observed epidemic dynamics are the result of the aforementioned key
62 evolutionary and epidemiological processes, in this study, we utilized a long-term influenza
63 incidence surveillance dataset collected in Hong Kong since 1998 to estimate the timing of
64 punctuated antigenic changes, strength of cross-immunity, duration of immunity, as well as
65 other key epidemiological parameters for each of the three types/subtypes. Hong Kong is a
66 subtropical city located in Southeast Asia. Unlike the highly seasonal epidemics in

67 temperate regions, in the subtropics and tropics, influenza epidemics can occur at any time
68 of the year (32, 33) and, often, multiple types/subtypes co-circulate causing co-epidemics
69 of comparable magnitude. The long-term Hong Kong dataset with diverse epidemics thus
70 provides a unique opportunity to study the interplay of different influenza types/subtypes
71 at the population level.

72

73 These highly diverse epidemic dynamics, however, also present major challenges
74 for inference on transmission dynamics. In an exploratory analysis, we coupled a
75 commonly used multi-strain susceptible-infected-recovered-susceptible (SIRS) model (24)
76 with a particle filter (34-36), a Bayesian inference method, and applied it to the Hong Kong
77 dataset. While this model-inference system was able to reproduce the observed epidemic
78 pattern, the model state did not appear to converge (see Fig. S1). Three major challenges
79 exist. First, the seasonality of influenza in part shapes the epidemic dynamics and thus
80 should be accounted for in the model. However, unlike the winter-time epidemics in
81 temperate regions that have been well-characterized by seasonal forcing of climate
82 variables (humidity alone or with temperature) (37, 38), to date no models capable of
83 capturing the diverse seasonal pattern in tropical and subtropical climates exist. Second, to
84 estimate epidemiological parameters such as the duration of immunity, the inference
85 system must be able to preserve such long-term epidemic features. Single-pass filters (e.g.,
86 the particle filter) did not appear to do so as seen in our exploratory analysis. Multi-pass
87 filters (e.g., iterated filters (39-41)) have such built-in capability, however, are less adept in
88 modeling diverse epidemic dynamics (42). Finally, it is challenging to estimate a large
89 number of parameters needed to characterize the interactions between virus-pairs.

90

91 We therefore developed a model-inference system that addresses the above
92 challenges. The basic reproductive number R_0 is a key epidemiological parameter
93 describing the transmissibility of an infection, defined as the average number of secondary
94 infections that arise from a primary infection in a naïve population. We thus first estimate,
95 for each influenza type/subtype, the average R_0 in each week of the year based on the
96 average annual epidemic cycle, i.e. the empirical seasonal cycle. We then incorporate this
97 R_0 seasonal cycle (as the prior distribution) in the model-inference system to control for
98 the seasonality observed in Hong Kong. For the second challenge, we combine the IF2
99 iterated filtering algorithm (41) with space re-probing (36, 43), a technique that allows
100 continuous exploring of state space. The combined SR-IF2 inference method coupled with
101 the empirical seasonal multi-strain SIRS model is thus able to preserve the long-term
102 epidemic feature while adeptly explore the state space to capture the epidemic dynamics.
103 To estimate parameters in high dimensional state space, we take a multi-round inference
104 strategy; in the first round, we parse the entire state space into subspaces and test each to
105 find the optimal subspace; subsequent rounds then build on the previous one until the
106 model estimates converge. Indeed, testing using model-generated mock epidemics
107 indicates that this model-inference system and optimization strategy is able to recover the
108 true model state variables and parameters (*SI Appendix* and Figs S2 and S3).

109

110 Here we apply the validated model-inference system to the Hong Kong dataset and
111 infer how major antigenic evolutions and cross-immunity affect influenza transmission
112 dynamics therein over the last 20 years. Our results reveal intricate ecological interactions

113 among the three co-circulating influenza types/subtypes and their impacts on long-term
114 influenza epidemic dynamics.

115

116 **Results**

117 **Overall influenza epidemic characteristics and seasonal cycles in Hong Kong.** During

118 Jan 1998—July 2018 (~20 years), there were 17 A(H1N1), 21 A(H3N2), and 18 B

119 epidemics, respectively (or 13, 19 and 14, respectively, if only counting larger epidemics;

120 see *SI Appendix* and Figs. S4 and S5 for divisions of individual epidemics). Figure 1 shows

121 the superimposed annual cycle for each influenza type/subtype in Hong Kong during the

122 study period and the average cycle excluding 2009 for the A(H1N1) pandemic in that year.

123 All three types/subtypes were able to circulate any time in the year. Epidemics of A(H1N1)

124 and A(H3N2) occurred in both winter and summer with similar magnitudes (Fig 1 A and

125 B). In comparison, for influenza B, major epidemics tended to occur in winter months (Fig

126 1C). As a result, the estimated R_0 seasonal cycle has clear bimodal peaks for the two A

127 subtypes (Fig 1 D and E), although to a less extent for A(H1N1); and for type B, it has only

128 one peak in the winter.

129

130 **Model-fits to influenza epidemic dynamics in Hong Kong (1998–2018).** Figure 2 shows

131 the model-fits to the epidemic curves of the three influenza types/subtypes. Despite the

132 highly irregular epidemic timing and intensity, the model-inference system, run

133 continuously through the entire 20-year study period, was able to recreate the observed

134 epidemic dynamics for all three types/subtypes. Distributions of residuals were centered at

135 0, indicating no systematic biases of the model (Fig S6). In addition, the model-inference

136 system was able to accurately estimate the infection rates during both epidemic and non-
137 epidemic periods for all types/subtypes. In particular, over the 20-year study period,
138 epidemics of A(H1N1) were less frequent compared to the other two types/subtypes. For
139 instance, few A(H1N1) cases were reported during Jan 1998 – Dec 1999 (the entire 2-year
140 period) and May 2002 – Dec 2004 (the entire 2.5-year period). While R_0 followed the same
141 seasonal cycle as years with epidemics (Fig 3A), the estimated infection rates remained at
142 near-zero over these extended time-periods when A(H1N1) was not in circulation (Fig 2A).

143
144 In addition to running the model continuously without re-initiation to correct for
145 model errors, we included a continuous seeding at a constant rate of 1 case per 100,000
146 population per 10 days for all types/subtypes. This epidemic seeding represents travel-
147 related importation of cases into local population, since Hong Kong is a transportation hub
148 highly connected to places worldwide. This seeding is also designed to test the accuracy of
149 estimates of key model state variables and parameters, as they are intricately linked to the
150 infection rate. Foremost, overestimation of population susceptibility would lead to
151 overestimation of cases during non-epidemic periods, as the seeded cases would lead to an
152 epidemic should the effective reproductive number R_e (computed as R_0 times population
153 susceptibility) be above unity and sustain so. Conversely, underestimation of susceptibility
154 would lead to underestimation of cases during epidemic periods or require unrealistically
155 frequent antigenic changes prior to an epidemic. Further, population susceptibility is also
156 linked to the duration of immunity and the strength of cross-immunity. Loss of immunity
157 (determined by the immunity period) replenishes the susceptible pool whereas gaining of
158 cross-immunity from infection by other types/subtypes (determined by the strength of

159 cross-immunity) can reduce susceptibility. As such, estimates of these related parameters
160 should also be accurate in order to achieve accurate estimation of infection rate. Taken
161 together, the accurate infection rate estimates suggest that the model-inference system was
162 also able to accurately estimate key state variable variables and parameters.

163

164 **Population susceptibility, R_0 , infectious period, and immunity period.** Table 1

165 summarizes the estimates of key epidemiological parameters for each influenza (sub)type.

166 Weekly estimates are shown in Fig 2 (susceptibility), Fig 3 (R_0 and R_e), and Fig S7

167 (infectious period, immunity period, and cross-immunity). During Jan 1998 – July 2018,

168 estimated population susceptibility was higher for A(H1N1) and B than A(H3N2) (Fig 2).

169 The mean levels and ranges were 66.6% (range: 50.9–90.3%) for A(H1N1), 60.8% (46.4–

170 89.0%) for A(H3N2), and 68.6% (50.6–87.8%) for B, respectively. These estimates were

171 consistent with the relative infection rates of individual types/subtypes. Note, however,

172 due to stringent public health interventions (i.e., case isolation, contact tracing, and school

173 closure) implemented from early May to mid-July 2009 (44) and self-protection (e.g.,

174 improved personal hygiene and social distancing) during that time (45), the pandemic in

175 Hong Kong unfolded relatively slowly and estimated population susceptibility at the

176 beginning of the 2009 pandemic was relatively low (~71% in mid-July; Fig 2).

177

178 The basic reproductive number R_0 was in general higher for A(H3N2) (1.6; range:

179 1.3–2.0) than A(H1N1) (1.4; 1.1–1.8) and B (1.4; 1.1–1.8). Estimated R_0 for the A(H1N1)

180 pandemic in mid-July 2009 was 1.5 (95% CI: 1.3, 1.8), similar to previous estimates (46).

181 The mean effective reproductive number R_e , while fluctuated over time (Fig 3B), did

182 average to unity over the 20-year study period for all types/subtypes. The estimated
183 infectious period was slightly longer for A(H3N2) (3.0; 2.6–4.3 days) and B (3.1; 2.2–4.1
184 days) than A(H1N1) (2.6; 2.2–3.8 days).

185
186 The length of immunity period determines the duration of immune protection from
187 prior infection and is thus a key epidemiological parameter shaping the long-term
188 dynamics of influenza epidemics. However, it remains difficult to estimate due to the
189 complex nature of immunogenicity and lack of detail, longitudinal serological data (47, 48).
190 Given the uncertainty, we tested a wide prior range from 1 to 9 years. The posterior
191 estimate of immunity period (Table 1 and Fig S7) was about 3 years for both A(H1N1) (3.1;
192 2.6–4.0 years) and B (3.1; 2.7–3.5 years), and shorter for A(H3N2) (2.2; 1.8–2.6 years).
193 These estimates accounted for cross-immunity from infections of other types/subtypes, for
194 which, after conversion based on the strength of cross-immunity, was treated the same as
195 specific-immunity from the same type/subtype (see Eqn 1 in Methods).

196
197 **Key ecological interactions via cross-immunity.** The strength of cross-immunity may
198 modulate the ecological completion among co-circulating influenza viruses. Here we
199 estimated the pair-wise cross-immunity strength, relative to specific-immunity from the
200 same type/subtype (Table 1 and Fig S7; c_{ij} denotes cross-immunity against virus- i gained
201 from infection of virus- j). Three interesting features seem to characterize the interactions
202 between the three influenza types/subtypes. First, interactions are asymmetric (i.e., $c_{ij} \neq c_{ji}$)
203 and cross-immunity appears to be weaker from types/subtypes with higher mutation
204 rates. In particular, among all virus-pairs, cross-immunity was the weakest when gained

205 from infection of A(H3N2) (the mean was 17% of the strength of specific-immunity against
206 A(H1N1) and 11% against B). Second, as expected, homotypic- is stronger than heterotypic
207 cross-immunity. Among all virus-pairs, cross-immunity from A(H1N1) against A(H3N2)
208 was the strongest (40%; 23–56%). Third, cross-immunity appears to mediate ecologic
209 competition among the three influenza types/subtypes, with B "controlling" A(H1N1) and
210 the latter further "controlling" A(H3N2). Specifically, the second strongest cross-immunity
211 was from B against A(H1N1) (32%; 26–40%); this, along with the strong cross-immunity
212 from A(H1N1) against A(H3N2), formed a control cascade of $B \rightarrow A(H1N1) \rightarrow A(H3N2)$. The
213 higher mutation rate of A(H3N2) virus (4) then allowed it to escape prior immunity
214 including cross-reactive ones from A(H1N1) and B. On the other hand, cross-immunity
215 from A(H1N1) against B (23%; 19–32%) was comparable to the reverse, allowing the two
216 viruses to maintain a more balanced bidirectional ecologic competition.

217

218 As our estimates that cross-immunity from A(H1N1) against A(H3N2) is stronger
219 than the reverse appeared to contradict previous notion that A(H3N2) outcompetes
220 A(H1N1) (see, e.g., (49)), we further used model-simulation to test the long-term impact of
221 cross-immunity under three different scenarios: 1) As estimated here, i.e., setting all cross-
222 immunity terms to the posterior mean estimates; 2) A(H3N2) outcompeting A(H1N1) via
223 stronger cross-immunity, for which we set $c_{H1 \leftarrow H3}$ to 0.5 (vs. 0.4 for $c_{H3 \leftarrow H1}$); and 3) No
224 interactions, i.e., setting all cross-immunity terms to 0 (see details in *SI Appendix* and
225 simulated epidemics in Figs. S8-10). As shown in Fig. S11, scenario 1 most closely
226 reproduced the observed pattern of co-circulation. In contrast, scenario 2 (i.e., A(H3N2)
227 outcompeting A(H1N1)) largely underestimated the frequency of A(H1N1) epidemics,

228 whereas scenario 3 (i.e., no cross-immunity) largely overestimated the frequency of co-
229 epidemics caused by multiple types/subtypes.

230

231 **Timing and frequency of punctuated antigenic changes.** Analyses of the antigenic
232 evolution of influenza have shown that major antigenic changes occur in a punctuated
233 fashion, allowing substantial increases in population susceptibility and in turn surge of
234 influenza epidemic (4, 26, 50). To capture such punctuated antigenic changes, our model-
235 inference system allowed abrupt increases in population susceptibility in response to
236 unexpected epidemic surges that are potentially due to major antigenic evolutions in the
237 influenza virus. We then used the major increases in population susceptibility (i.e., >15%
238 increase relative to the preceding week; results using 10% as cutoff are consistent; see
239 Table S1) to identify potential punctuated antigenic changes. Over the 20-year study
240 period, we detected such major changes in population susceptibility 7 times for A(H1N1),
241 including two due to the 2009 pandemic (Fig 2A), 12 times for A(H3N2) (Fig 2B), and 4
242 times for B (Fig 2C). Table 2 shows the estimated timing of each potential antigenic
243 innovation. Based on these estimates, punctuated antigenic changes occurred every 4.6
244 (SD=4.6; exponential distribution) years in A(H1N1) (excluding the 2009 pandemic), 1.8
245 (SD=1.2; gamma distribution) years in A(H3N2), and 6.2 (SD=6.2; exponential distribution)
246 years in B during Jan 1998 – July 2018. These results are consistent with reported
247 estimates based on antigenic testing of influenza virus isolates (4, 50). Further,
248 interestingly, for A(H3N2), such potential antigenic innovations occurred with comparable
249 frequencies in both summers (7 times in May, June or July) and winters (5 times in Jan or

250 Feb) during the 20-year study period. In contrast, it occurred mostly in winters for
251 A(H1N1) and only in winters for B.

252

253 **Discussion**

254 Cross-immunity among different influenza viruses has been reported and its resulting
255 potential interactions have been modeled; however, to date, its strength and impact on
256 influenza transmission dynamics at the population level remains unclear. Utilizing a long-
257 term incidence surveillance dataset in Hong Kong since 1998, here we have quantified the
258 strength of cross-immunity among the two influenza A subtypes and B currently co-
259 circulating in humans and the pattern of viral interactions. We have also estimated the
260 timing and frequency of punctuated surges in population susceptibility representing
261 population-level response to antigenic innovations in influenza viruses over the last 20
262 years as well as identified key variations among three influenza types/subtypes. These
263 estimates, along with other key epidemiological variable estimates including the
264 population susceptibility and basic reproductive number, provide great insight into the
265 evolutionary and epidemiological dynamics of influenza.

266

267 **Comparing transmissibility of influenza in Hong Kong and elsewhere.** Influenza
268 epidemics in subtropical Hong Kong are highly diverse and frequent (Fig1 and Figs. S4 and
269 S5). Nevertheless, R_0 estimates across all three types/subtypes are in the range of 1.1 to
270 2.0, similar to previous estimates in other regions for influenza overall (51). Few studies
271 have estimated R_0 for individual influenza types/subtypes, especially for inter-pandemic
272 seasons. Here we estimate that R_0 was similar for A(H1N1) and B (range: 1.1–1.8 for both)

273 and was slightly higher for A(H3N2) (range: 1.3–2.0). Estimated simultaneously with R_0 ,
274 the infectious period, or generation time, was slightly longer for A(H3N2) and B than
275 A(H1N1); these estimates were very close to those based on viral shedding curves—3.0 vs
276 3.1 days reported for A(H3N2), 3.1 vs 3.4 days reported for B, and 2.6 vs 2.3 days reported
277 for A(H1N1) (52). Together, the higher transmissibility of A(H3N2) (i.e., larger R_0 and
278 longer infectious period) in part explains its larger seasonal epidemics and resulting lower
279 average population susceptibility (mean: 60.8% for A(H3N2) vs. 66.6% for A(H1N1) and
280 68.6% for B). Further, these consistent estimates indicate that our strategy using the
281 empirical R_0 seasonal cycle in the model-inference system is effective in controlling for the
282 elusive influenza seasonality in Hong Kong and allows for estimation of other key
283 epidemiological features. Future studies could apply the same strategy to study the diverse
284 influenza dynamics in other subtropical/tropical regions or other infections with similar
285 challenges.

286

287 **Cross-immunity and co-circulation pattern.** Multiple lines of evidence have suggested
288 cross protection offered by infection of influenza viruses of the same type/subtype as well
289 as across types/subtypes (7-18). However, some studies have reported weak or no
290 heterosubtypic and/or heterotypic cross-immunity (47, 53). As noted by authors of those
291 studies, the cross-sectional serological surveys used therein may miss the window of cross-
292 immunity and/or immunity mechanisms not related to antibodies against the
293 hemagglutinin surface protein (e.g., from T cells mediated immunity). In this study, based
294 on the long-term type/subtype-specific incidence data, we estimate that there were
295 relatively strong cross-immunity against A(H3N2) by infection of A(H1N1) (~40% of the

296 specific-immunity) and moderate level of cross-immunity between A(H1N1) and B (20-
297 30%). Consistently, our simulations showed that interactions among the three
298 types/subtypes are needed to produce the pattern of co-circulation observed in Hong Kong
299 (Fig. S11 and Fig. S8 vs. Fig. S10).

300
301 However, our estimates of weak cross-immunities to A(H1N1) and B conferred by
302 infection of A(H3N2) appear to contradict the common notion that A(H3N2) outcompetes
303 A(H1N1) and B and, as a result, causes more frequent and larger epidemics. For instance,
304 Goldstein et al. (49) showed a negative correlation between early A(H3N2) incidence and
305 subsequent non-A(H3N2) incidence in the same season, suggesting A(H3N2) may interfere
306 with the other two types/subtypes. To test this discrepancy, we simulated epidemics under
307 both scenarios and showed that combining the frequent and large epidemics of A(H3N2)
308 with stronger cross-immunity conferred would likely drive A(H1N1) to extinction (see Fig.
309 S9; note epidemics of A(H1N1) were only possible after the imposed antigenic
310 innovations). Conversely, the strong cross-immunity from A(H1N1) against A(H3N2), as
311 estimated in this study, is consistent with the predominant circulation of A(H1N1) during
312 the 2009 pandemic despite the frequent circulation of A(H3N2) during inter-pandemic
313 seasons.

314
315 Thus, to understand the co-circulation pattern of influenza viruses, we need to take
316 into account other key epidemiological features. In particular, A(H3N2) confers shorter
317 immunity following infection and also undergoes more frequent genetic/antigenic
318 mutations. Based on the estimated mean immunity period and implicit assumption of

319 exponential distribution in the model (Eqn 1), the mean half-life of immunity (i.e. $\ln 2$ times
320 of the mean) was 1.6 years for A(H3N2), 2.2 years for A(H1N1), and 2.1 years for B. Note
321 our estimates were shorter than reported elsewhere (e.g., 3.5 to 7 years in (47, 48)), likely
322 because, unlike those studies based on titers of antibodies against specific strains, our
323 estimates broadly applied to the entire type/subtype. Nevertheless, the relative lengths of
324 immunity period for the three influenza types/subtypes were consistent. A recent cohort-
325 specific analysis (54) further showed that birth-cohorts whose first exposure was A(H1N1)
326 had long-term protection against subsequent infection by the same subtype whereas those
327 first exposed to A(H3N2) did not (See Table 4 in ref (54)). It is thus likely that A(H3N2)
328 virus' shorter/weaker immunity and more frequent mutations lead to more frequent
329 A(H3N2) epidemics, and that combining its larger epidemic size and weaker cross-
330 immunity (roughly, the product of these two factors is the decrease in susceptibility to its
331 complement types/subtypes) allows the two less frequently circulating influenza
332 types/subtypes to coexist in humans.

333

334 **Estimating timing and frequency of antigenic innovations based on incidence data.**

335 Unlike previous analyses of genomic and/or antigenic data, here we tentatively estimate
336 the timing and frequency of punctuated antigenic innovations based on incidence data
337 alone. The rationale is that punctuated antigenic innovations in influenza viruses would
338 lead to surge in population susceptibility and subsequently surge in incidence. That is,
339 incidence data encapsulate the population response to antigenic innovations and thus may
340 complement analyses of genomic and/or antigenic data (note the latter do not provide
341 information as to if an antigenic mutation would lead to an epidemic). Indeed, our results

342 are consistent with estimates from phylogenetic analyses. For instance, the two surges in
343 susceptibility to A(H1N1) during the 2009 pandemic (i.e., around 9/13/09 and 1/5/10;
344 Table 2) roughly matched with the estimated timings of amino acid mutations from
345 NextStrain (55): 1) HA1: S185T and HA2: S124N around 10/1/09 (CI: 7/26/09-1/16/10)
346 and 2) HA1: D97N round 10/30/09 (CI: 09/03/09-02/07/10). In addition, previous
347 studies estimated that punctuated antigenic innovations occur roughly every 2 to 8 years in
348 A(H3N2) (26, 50), 4 to 9 years in A(H1N1), and 3 to 14 years in B (4), based on antigenic
349 analysis of influenza virus isolates. Consistently, we estimate that antigenic innovations
350 occurred very 4.6 ± 4.6 years in A(H1N1), every 1.8 ± 1.2 years in A(H3N2), and every 6.2 ± 6.2
351 years in B during Jan 1998–July 2018. These consistent results suggest incidence
352 surveillance data could be an inexpensive alternative to support detection of evolutionary
353 changes in influenza viruses, especially since these estimates reflect changes in population
354 immunity in response to antigenic innovations and thus the potential of epidemic surge.

355
356 In addition, we note the different seasonal timing of antigenic innovations for
357 A(H3N2). While the identified antigenic innovations predominantly occurred in winters for
358 A(H1N1) and B, we find that A(H3N2) could undergo major antigenic changes in both
359 summers and winters. Further investigation is warranted, as, if confirmed, this seasonality
360 suggests that sampling A(H3N2) strains in the summer may be essential for selection of
361 vaccine strains.

362
363 Our study has several limitations. First, as B lineage data were only available since
364 2014 in Hong Kong, in this study, we did not differentiate the two B lineages (i.e. Yamagata

365 and Victoria). Future work will extend the model-inference system to include and test the
366 epidemiological interactions with the two B lineages. Second, while using the empirical
367 seasonal cycle to account for the epidemic seasonality in Hong Kong has proven critical in
368 this study and may be applied to other subtropical and tropical regions with similar diverse
369 epidemics, better delineation of influenza seasonality in these climates is needed. Third,
370 we assumed that the probability of seeking medical attention for influenza is comparable to
371 other illnesses and, for simplicity, we did not consider the differences in health seeking
372 behavior among patients infected by different influenza (sub)types. Based on this
373 assumption, the estimated annual attack rates ranged from 13% in 2013 to 42% in 2005.
374 There is large uncertainty in estimated influenza attack rates. Recent estimates ranged
375 from 3-11% *symptomatic* infections among vaccinated and unvaccinated US residents
376 during 2010-2016 (56) to 32% confirmed infection among unvaccinated individuals during
377 2015 in New Zealand (57). In comparison, our estimates for Hong Kong are relatively high
378 but plausible given the longer epidemic duration and lower vaccination rates in Hong Kong
379 (~10% (58, 59) v. ~45% in the US (60)). It could also be due to overestimation of A(H3N2)
380 incidence rates, as patients infected with A(H3N2) may be more likely to seek treatment
381 due to more severe symptoms compared to A(H1N1) and B. Further, while we calibrated
382 the incidence rates of A(H1N1) during the 2009 pandemic to the estimated attack rate from
383 serological data (see Methods), our model-inference system did not include public health
384 interventions implemented particularly at the beginning of the pandemic. As a result, our
385 model-inference system—entirely based on incidence data—likely underestimated the
386 increase in susceptibility at the onset of the pandemic. Nevertheless, the estimated timing
387 of antigenic innovations (6 July 2019) was very close to the observed onset of the pandemic

388 in Hong Kong (30 June 2019 (61)). Finally, due to a lack of age-specific incidence data and
389 for simplicity, we did not include age structure in our model. Recent studies have reported
390 differences in immune imprinting in children compared to adults (47, 48). Future work
391 may investigate such age differences further should age-specific incidence data become
392 available.

393
394 In summary, using a comprehensive model-inference system, we have revealed in
395 great detail the epidemiological interactions among the three influenza types/subtypes, the
396 antigenic innovations for each type/subtype, and their combined impact on the
397 transmission dynamics of influenza over the last two decades in Hong Kong, a city of global
398 public health significance for influenza epidemic and pandemic control. The intricate
399 epidemiological interactions among influenza viruses and key underlying population
400 features underscore the importance of monitoring population immunity to different
401 influenza viruses, incidence rates, and viral genetic and antigenic changes. Meanwhile, the
402 model-inference system developed here has proven powerful for estimating key
403 evolutionary and epidemiological characteristics of influenza viruses based on
404 type/subtype-specific incidence data and could be extended to study influenza epidemic
405 dynamics in other regions with limited antigenic data.

406

407 **Materials and Methods**

408 **Influenza surveillance data.** The Centre for Health Protection in Hong Kong monitors
409 seasonal influenza activity through a sentinel surveillance network of approximately 50
410 private-sector outpatient clinics that report weekly proportion of outpatients presenting

411 with influenza-like illness (ILI; defined as fever >38.0°C plus cough and/or sore throat)
412 (62-64). In addition, the Public Health Laboratory Services Branch thereof conducts
413 laboratory testing for influenza viruses in samples submitted mainly from local hospitals
414 and also a small number of samples submitted by the sentinel outpatient physicians. We
415 obtained weekly records of ILI consultation rate and concurrent (sub)type-specific
416 influenza detection rate from the week ending 04 Jan 1998 to the week ending 14 July
417 2018. To obtain a more specific measure of the incidence of influenza virus infections in the
418 community, we multiplied the weekly ILI rate by the concurrent viral isolation rate for
419 A(H1N1), A(H3N2) and B, respectively (42, 49, 65, 66). We refer to these combined
420 measures as A(H1N1)+, A(H3N2)+, and B+.

421

422 *Converting ILI consultation rate to infection rate*

423 The ILI consultation rate is the ratio of patients presenting ILI to all patient-visits and does
424 not measure true influenza incidence rate in the catchment population. Previously, we
425 showed that conversion to *per-capita* infection rate can be made based on Bayes' rule (65,
426 67). Briefly, ILI+ (here, ILI+ = A(H1N1)+, A(H3N2)+, or B+) estimates the probability that a
427 person seeking medical attention, m , has influenza, i.e., $p(i|m)$. By Bayes' rule, the incidence
428 rate, or probability of a person contracting influenza during a given week, $p(i)$, is:

$$429 \quad p(i) = \frac{p(m)}{p(m|i)} ILI_+$$

430 This formula can thus convert ILI+ to the incidence rate $p(i)$ if $\gamma = \frac{p(m)}{p(m|i)}$ is known.

431 In our previous work, we estimated the conversion factor γ along with other model state
432 variables and parameters using a model-inference system without strain-interactions (36).

433 Here to reduce model uncertainty and complexity, we estimated γ separately based on
434 independent estimates of attack rate during the pandemic. Based on serological data,
435 estimated attack rates for the 2009 pandemic ranged from 16% (68) to ~20% (61, 69).
436 Using the upper end of these estimates and the cumulative pandemic H1N1+ rate over the
437 same time period (i.e., 42%), the conversion factor γ is ~0.5 for the pandemic. For the inter-
438 pandemic period, we set $\gamma=1$, which resulted in annual attack rates ranging from 13% in
439 2013 and 42% in 2005. The attack rate in 2005 was the highest due to epidemics of all
440 three types/subtypes in the same year (3.3%, 31.1%, and 7.4% attack rates for A(H1N1),
441 A(H3N2), and B, respectively). These estimates are higher than temperate regions but
442 plausible given the year-round circulation of influenza and low vaccination rates in Hong
443 Kong.

444

445 **Estimating the empirical seasonal cycle of influenza epidemic.** As discussed in the
446 Introduction, the seasonality of influenza epidemics in Hong Kong is weaker than in
447 temperate locations. To model this seasonality, we first computed the weekly average of
448 incidence rate over the study period, excluding year 2009 during which seasonality may be
449 altered due to the A(H1N1) pandemic. We then estimated the time-varying R_0 for each
450 week of the year using a model-inference system we previously developed for Hong Kong
451 (36). This system used a basic Susceptible-Infectious-Recovered (SIR) model and ran it
452 with a particle filter with space re-probing. We further smoothed the posterior estimates
453 of R_0 using 3-week moving average and used these estimates as the prior in the multi-strain
454 SIRS model-inference system (described below) to represent the empirical seasonal cycle.

455

456 **Multi-strain SIRS model.** A number of mathematical models have been developed (19-29,
457 70-73) to study the interplay of influenza viruses. The central idea behind these models is
458 that cross-immunity can either reduce the chance of reinfection and transmission in any
459 individual with prior infection by a similar strain (i.e. leaky immunity) or protect a portion
460 of individuals with prior infection (i.e. polarized immunity). In particular, Gog and Grenfell
461 (24) developed a parsimonious status based multi-strain model by assuming polarized
462 immunity and cross-immunity acted to reduce transmission risk. This model is able to
463 generate evolutionary dynamics similar to that observed for influenza and is commonly
464 used as the backbone for more complex phylodynamic models (26, 28, 73, 74). The multi-
465 strain SIRS model in this study took a construct similar to the Gog & Grenfell model:

$$\begin{cases} \frac{dS_i}{dt} = - \sum_j \frac{c_{ij}\beta_j S_j I_j}{N} + \frac{N - S_i - I_i}{L_i} + \mu(N - S_i) - \alpha \\ \frac{dI_i}{dt} = \frac{\beta_i S_i I_i}{N} - \frac{I_i}{D_i} - \mu I_i + \alpha \end{cases} \quad [1]$$

466
467 where N is the population size; S_i and I_i , are, respectively, the numbers susceptible and
468 infected, to virus- i (here A(H1N1), A(H3N2), or B); β_i , D_i , and L_i are, respectively, the
469 transmission rate, mean infectious period, and mean immunity period, for virus- i ; and c_{ij}
470 measures the strength of cross-immunity to virus- i conferred by infection of virus- j (e.g.,
471 close to 0 if it is weak and $c_{ii}=1$ for strain-specific immunity). We assumed the total
472 population size is stable over the study period such that the birth rate and death rate are
473 equal and both are represented by parameter μ . The parameter α represents travel-related
474 importation of cases and for simplicity was set to 0.1 per 100,000 per day throughout the
475 study period. The model was run continuously in daily time-step from 1 Jan 1998 to 14 July

476 2018 in conjunction with the SR-IF2 filter (described below), during which
477 variables/parameters were updated weekly at the arrival of observations.
478
479 **Inference on transmission dynamics using the SR-IF2 algorithm.** We applied a
480 modified IF2 algorithm (termed SR-IF2) to estimate the model state variables and
481 parameters for each week in the 20-year study period. The original IF2 algorithm,
482 developed by and described in detail in Ionides et al (41, 75), implements an iterated,
483 perturbed Bayes map for inference of partially observed dynamic systems. In each
484 iteration, it uses a particle filter (34) to estimate the likelihood of the observed time series
485 (here the A(H1N1)+, A(H3N2)+, and B+ time series altogether). The particle filter uses a
486 suite of model replicates, each is initially randomly drawn from the prior, to represent
487 samples of the latent dynamic variables. Over the course of filtering, the particles are
488 numerically integrated forward in time per the dynamic model (here the multi-strain
489 model in Eqn 1) and resampled based on the likelihood to update the distribution of all
490 model parameters/variables per Bayes' rule at each time step (here each week). At the end
491 of the time series, model parameters are recycled as starting parameters for the next
492 iteration. In theory, this procedure converges to the maximum likelihood estimate.

493
494 While the original IF2 incorporates perturbations of model parameters, our
495 preliminary tests showed that these perturbations alone are insufficient to capture the
496 unexpected surges in population susceptibility due to potential punctuated antigenic
497 changes in the influenza virus. To tackle this issue, we further incorporated space re-
498 probing (SR) in the IF2. Briefly, the SR step allows a small fraction (here 1%) of the model

499 ensemble to sample from the full prior range for key model variables/parameters (here,
500 the susceptibility), whenever filter divergence is detected (i.e., the likelihood drops below a
501 threshold); in addition, to capture other possible changes in parameters related to the virus
502 (e.g., R_0 and strength cross-immunity), we set time points requiring SR as break-points, for
503 which larger perturbations are applied to all model parameters/variables (75).

504

505 The priors for initiating the SR-IF2 were uniform distributions as follows:

506 $S_i \sim U[50\%, 90\%]$ of total population and $D_i \sim U[2, 4]$ days for $i=A(H1N1)$, $A(H3N2)$, or B. To
507 account for seasonality of each (sub)type, the prior of R_0 for week t of the year was drawn
508 from a uniform distribution with a range of the mean empirical estimate for that week
509 plus/minus one standard deviation. Correspondingly, the prior of transmission rate β_i for
510 week t of the year was then computed as $R_{0,i}(t)/D_i(t)$. For the immunity period L_i , given the
511 wide range reported in the literature (from months to ~ 8 years (76, 77)), we tested prior
512 ranges from 1 to 9 years, divided into four 2-year segments (i.e., [1, 3], [3, 5], [5, 7], and [7,
513 9] years) for each type/subtype; this resulted in $4^3=64$ combinations for the three
514 type/subtypes. Cross-immunity has been observed for influenza strains of the same
515 subtype as well as across types/subtypes (7-15) and types (16-18); however, the strength
516 has rarely been reported. We thus tested prior ranges from 0% to 80% of the strength of
517 specific immunity, divided into two levels: [0%, 40%] (low) and [40%, 80%] (high); this
518 resulted in $2^6=64$ combinations for 6 virus-pairs (c_{ij} , $i=H1N1, H3N2$, or B and $j \neq i$). To
519 reduce the number of combinations, *a priori*, we further assumed that heterotypic cross-
520 immunity is low especially when the immunity period (L_i) is long; thus, for $L_i > 5$ years, we
521 only included combinations with low A(H1N1) (or H3N2) and B interactions. Note,

522 however, with perturbations in the IF2 procedure, the posterior estimates can go outside
523 the prior range. Together, we tested a total of 736 combinations of L_i and c_{ij} priors in the
524 first round of search. We then selected the top $\sim 1\%$ runs with the best model-fits (highest
525 likelihood *and* fewest space re-probing needed) used their posterior estimates to compute
526 the prior range for subsequent round of search. We repeated this process until the
527 parameters converge. It took two rounds for the synthetic data and three rounds for the
528 observed data.

529
530 For each SR-IF2 model-inference run, we performed 50 iterations of filtering with
531 5000 particles. Each run took round 8 to 10 hours to complete on a high-performance
532 cluster ([https://www.mailman.columbia.edu/information-for/information-](https://www.mailman.columbia.edu/information-for/information-technology/high-performance-computing-hpc)
533 [technology/high-performance-computing-hpc](https://www.mailman.columbia.edu/information-for/information-technology/high-performance-computing-hpc)). To account for stochasticity in model
534 initiation, we performed 5 runs for each prior in the first round and 50 runs in the second
535 and third round (i.e., final round for the observed data). From the final round, we selected
536 ~ 10 runs with the best model-fits (highest likelihood *and* fewest space re-probing needed)
537 and computed the posterior estimates across those runs per Rubin's rule (78, 79).

538
539 **Estimating the timing and frequency of punctuated antigenic change.** To identify
540 potential punctuated antigenic changes for each (sub)type, we computed the changes in
541 susceptibility for each week and considered weeks with a relative *increase* of 15% due to
542 punctuated antigenic changes. We also tested a cutoff of 10%, for which the identified
543 weeks were the same except for 2 additional weeks for A(H3N2) (1/10/1998 and

544 6/13/1999) and 1 for B (1/28/2001); these additional weeks were all in the early phase of
545 the study period and thus likely due to greater uncertainty in the model-inference system.

546

547 To estimate the mean time interval between punctuated antigenic changes, we
548 computed the time intervals between subsequent antigenic changes (right censored for the
549 last observation) and fitted these to four survival models (i.e., the exponential, Weibull,
550 gamma, and log-normal distribution) using the 'flexsurv' package (80) in R
551 (<https://www.r-project.org>). We selected the best model estimate based on the Akaike
552 Information Criterion (AIC).

553

554 **Acknowledgements:**

555 We thank the Hong Kong Center for Health Protection for providing data on sentinel
556 surveillance and laboratory surveillance for influenza. We also thank Columbia University
557 Mailman School of Public Health for access to high performance computing. **Funding:** WY
558 was supported by the NIH (1R03AI135926-01A1 and ES009089). EHYL and BJC were
559 supported by the Theme-based Research Scheme project no. T11-705/14N from the
560 University Grants Committee of the Hong Kong Government, and the National Institute of
561 General Medical Sciences (grant U54 GM088558 to the Harvard Center for Communicable
562 Disease Dynamics). Author contributions: Study conception (WY and BJC), model
563 development and implementation (WY), data curation (EHYL and BJC), result
564 interpretation (WY, EHYL, and BJC), first draft (WY), review and editing (WY, EHYL, and
565 BJC).

566 **Competing interests:** BJC reports receipt of honoraria from Roche and Sanofi. The authors

567 declare that they have no other potential competing interests.

568

569 **References:**

- 570 1. World Health Organization Influenza (Seasonal), Fact Sheet. Available at
571 <http://www.who.int/mediacentre/factsheets/fs211/en/> Accessed Jan 10, 2017
- 572 2. Iuliano AD, *et al.* (2018) Estimates of global seasonal influenza-associated respiratory
573 mortality: a modelling study. *Lancet* 391(10127):1285-1300.
- 574 3. Medina RA & Garcia-Sastre A (2011) Influenza A viruses: new research developments.
575 *Nature reviews. Microbiology* 9(8):590-603.
- 576 4. Bedford T, *et al.* (2014) Integrating influenza antigenic dynamics with molecular
577 evolution. *Elife* 3:e01914.
- 578 5. Bahl J, *et al.* (2011) Temporally structured metapopulation dynamics and persistence
579 of influenza A H3N2 virus in humans. *Proc Natl Acad Sci U S A* 108(48):19359-19364.
- 580 6. Smith DJ, *et al.* (2004) Mapping the antigenic and genetic evolution of influenza virus.
581 *Science* 305(5682):371-376.
- 582 7. Pica N & Palese P (2013) Toward a universal influenza virus vaccine: prospects and
583 challenges. *Annu Rev Med* 64:189-202.
- 584 8. Bodewes R, *et al.* (2011) Vaccination against seasonal influenza A/H3N2 virus reduces
585 the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in
586 ferrets. *J. Virol.* 85(6):2695-2702.
- 587 9. Ekiert DC, *et al.* (2009) Antibody recognition of a highly conserved influenza virus
588 epitope. *Science* 324(5924):246-251.

- 589 10. Ekiert DC, *et al.* (2011) A highly conserved neutralizing epitope on group 2 influenza A
590 viruses. *Science* 333(6044):843-850.
- 591 11. Epstein SL (2006) Prior H1N1 Influenza Infection and Susceptibility of Cleveland
592 Family Study Participants during the H2N2 Pandemic of 1957: An Experiment of
593 Nature. *J. Infect. Dis.* 193(1):49-53.
- 594 12. McMichael AJ, Gotch FM, Noble GR, & Beare PA (1983) Cytotoxic T-cell immunity to
595 influenza. *N. Engl. J. Med.* 309(1):13-17.
- 596 13. Miller MS, *et al.* (2012) 1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-
597 Hemagglutinin Stalk Antibodies in Humans. *J. Infect. Dis.* 207(1):98-105.
- 598 14. Sandbulte MR, *et al.* (2007) Cross-reactive neuraminidase antibodies afford partial
599 protection against H5N1 in mice and are present in unexposed humans. *PLoS Med*
600 4(2):e59.
- 601 15. Katz J, *et al.* (2009) Serum cross-reactive antibody response to a novel influenza A
602 (H1N1) virus after vaccination with seasonal influenza vaccine. *MMWR. Morb. Mortal.*
603 *Wkly. Rep.* 58(19):521-524.
- 604 16. Dreyfus C, *et al.* (2012) Highly Conserved Protective Epitopes on Influenza B Viruses.
605 *Science* 337(6100):1343-1348.
- 606 17. Stanekova Z & Vareckova E (2010) Conserved epitopes of influenza A virus inducing
607 protective immunity and their prospects for universal vaccine development. *Virology*
608 7:351.
- 609 18. Laurie K, *et al.* (2016) The time-interval between infections and viral hierarchies are
610 determinants of viral interference following influenza virus infection in a ferret model.
611 *Eur J Immunol* 46:685-686.

- 612 19. Andreasen V (2003) Dynamics of annual influenza A epidemics with immuno-selection.
613 *Journal of mathematical biology* 46(6):504-536.
- 614 20. Bansal S & Meyers LA (2012) The impact of past epidemics on future disease dynamics.
615 *Journal of theoretical biology* 309:176-184.
- 616 21. Boni MF, Gog JR, Andreasen V, & Christiansen FB (2004) Influenza drift and epidemic
617 size: the race between generating and escaping immunity. *Theor Popul Biol* 65(2):179-
618 191.
- 619 22. Casagrandi R, Bolzoni L, Levin SA, & Andreasen V (2006) The SIRC model and influenza
620 *A. Mathematical Biosciences* 200(2):152-169.
- 621 23. Chung KW & Lui R (2016) Dynamics of two-strain influenza model with cross-
622 immunity and no quarantine class. *Journal of mathematical biology* 73(6-7):1467-1489.
- 623 24. Gog JR & Grenfell BT (2002) Dynamics and selection of many-strain pathogens. *Proc*
624 *Natl Acad Sci U S A* 99(26):17209-17214.
- 625 25. Gog JR & Swinton J (2002) A status-based approach to multiple strain dynamics.
626 *Journal of mathematical biology* 44(2):169-184.
- 627 26. Koelle K, Cobey S, Grenfell B, & Pascual M (2006) Epochal evolution shapes the
628 phylodynamics of interpandemic influenza A (H3N2) in humans. *Science*
629 314(5807):1898-1903.
- 630 27. Koelle K & Rasmussen DA (2015) The effects of a deleterious mutation load on patterns
631 of influenza A/H3N2's antigenic evolution in humans. *Elife* 4:e07361.
- 632 28. Kucharski A & Gog JR (2012) Influenza emergence in the face of evolutionary
633 constraints. *Proc. R. Soc. B-Biol. Sci.* 279(1729):645-652.

- 634 29. Minayev P & Ferguson N (2009) Incorporating demographic stochasticity into multi-
635 strain epidemic models: application to influenza A. *Journal of the Royal Society Interface*
636 6(40):989-996.
- 637 30. Magal P & Ruan SG (2010) Sustained oscillations in an evolutionary epidemiological
638 model of influenza A drift. *P R Soc A* 466(2116):965-992.
- 639 31. Nuno M, Chowell G, Wang X, & Castillo-Chavez C (2007) On the role of cross-immunity
640 and vaccines on the survival of less fit flu-strains. *Theor Popul Biol* 71(1):20-29.
- 641 32. Wu P, *et al.* (2017) A joint analysis of influenza-associated hospitalizations and
642 mortality in Hong Kong, 1998-2013. *Sci Rep* 7(1):929.
- 643 33. Feng S, *et al.* (2018) Effectiveness of influenza vaccination on influenza-associated
644 hospitalisations over time among children in Hong Kong: a test-negative case-control
645 study. *Lancet Resp Med* 6(12):925-934.
- 646 34. Arulampalam MS, Maskell S, Gordon N, & Clapp T (2002) A tutorial on particle filters
647 for online nonlinear/non-Gaussian Bayesian tracking. *IEEE Trans. Signal Process.*
648 50(2):174-188.
- 649 35. van Leeuwen PJ (2009) Particle Filtering in Geophysical Systems. *Mon. Weather Rev.*
650 137(12):4089-4114.
- 651 36. Yang W, Cowling BJ, Lau EH, & Shaman J (2015) Forecasting Influenza Epidemics in
652 Hong Kong. *PLoS Comput Biol* 11(7):e1004383.
- 653 37. Shaman J, Pitzer VE, Viboud C, Grenfell BT, & Lipsitch M (2010) Absolute humidity and
654 the seasonal onset of influenza in the continental United States. *Plos Biol*
655 8(2):e1000316.

- 656 38. Axelsen JB, Yaari R, Grenfell BT, & Stone L (2014) Multiannual forecasting of seasonal
657 influenza dynamics reveals climatic and evolutionary drivers. *Proc Natl Acad Sci U S A*
658 111(26):9538-9542.
- 659 39. Ionides EL, Bhadra A, Atchade Y, & King A (2011) Iterated filtering. *Ann. Stat.*
660 39(3):1776-1802.
- 661 40. Ionides EL, Breto C, & King AA (2006) Inference for nonlinear dynamical systems. *Proc*
662 *Natl Acad Sci U S A* 103(49):18438-18443.
- 663 41. Ionides EL, Nguyen D, Atchade Y, Stoev S, & King AA (2015) Inference for dynamic and
664 latent variable models via iterated, perturbed Bayes maps. *Proc Natl Acad Sci U S A*
665 112(3):719-724.
- 666 42. Yang W, Karspeck A, & Shaman J (2014) Comparison of filtering methods for the
667 modeling and retrospective forecasting of influenza epidemics. *PLoS Comput Biol*
668 10(4):e1003583.
- 669 43. Yang W & Shaman J (2014) A simple modification for improving inference of non-linear
670 dynamical systems. *arXiv*:1403.6804.
- 671 44. Wu JT, *et al.* (2010) School closure and mitigation of pandemic (H1N1) 2009, Hong
672 Kong. *Emerging infectious diseases* 16(3):538-541.
- 673 45. Liao Q, Cowling B, Lam WT, Ng MW, & Fielding R (2010) Situational awareness and
674 health protective responses to pandemic influenza A (H1N1) in Hong Kong: a cross-
675 sectional study. *Plos One* 5(10):e13350.
- 676 46. Boelle PY, Ansart S, Cori A, & Valleron AJ (2011) Transmission parameters of the
677 A/H1N1 (2009) influenza virus pandemic: a review. *Influenza Other Respir Viruses*
678 5(5):306-316.

- 679 47. Ranjeva S, *et al.* (2019) Age-specific differences in the dynamics of protective immunity
680 to influenza. *Nat Commun* 10(1):1660.
- 681 48. Kucharski AJ, *et al.* (2015) Estimating the life course of influenza A(H3N2) antibody
682 responses from cross-sectional data. *Plos Biol* 13(3):e1002082.
- 683 49. Goldstein E, Cobey S, Takahashi S, Miller JC, & Lipsitch M (2011) Predicting the
684 epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statistical method. *PLoS Med*
685 8(7):e1001051.
- 686 50. Smith DJ, *et al.* (2004) Mapping the antigenic and genetic evolution of influenza virus.
687 *Science* 305(5682):371-376.
- 688 51. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, & Finelli L (2014) Estimates of the
689 reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic
690 review of the literature. *Bmc Infect Dis* 14:480.
- 691 52. Carrat F, *et al.* (2008) Time lines of infection and disease in human influenza: a review
692 of volunteer challenge studies. *Am J Epidemiol* 167(7):775-785.
- 693 53. Cowling BJ, *et al.* (2014) Incidence of influenza virus infections in children in Hong
694 Kong in a 3-year randomized placebo-controlled vaccine study, 2009-2012. *Clinical*
695 *infectious diseases : an official publication of the Infectious Diseases Society of America*
696 59(4):517-524.
- 697 54. Budd AP, *et al.* (2019) Birth Cohort Effects in Influenza Surveillance Data: Evidence
698 That First Influenza Infection Affects Later Influenza-Associated Illness. *The Journal of*
699 *infectious diseases* 220(5):820-829.

- 700 55. NextStrain.org Real-time tracking of influenza A/H1N1pdm evolution. Available at
701 [https://nextstrain.org/flu/seasonal/h1n1pdm/ha/12y?c=cTiter&f_country=hong_kon](https://nextstrain.org/flu/seasonal/h1n1pdm/ha/12y?c=cTiter&f_country=hong_kong)
702 [g](https://nextstrain.org/flu/seasonal/h1n1pdm/ha/12y?c=cTiter&f_country=hong_kong) Accessed
- 703 56. Tokars JI, Olsen SJ, & Reed C (2018) Seasonal Incidence of Symptomatic Influenza in the
704 United States. *Clinical Infectious Diseases* 66(10):1511-1518.
- 705 57. Huang QS, *et al.* (2019) Risk Factors and Attack Rates of Seasonal Influenza Infection:
706 Results of the Southern Hemisphere Influenza and Vaccine Effectiveness Research and
707 Surveillance (SHIVERS) Seroepidemiologic Cohort Study. *Journal of Infectious Diseases*
708 219(3):347-357.
- 709 58. Lee SS, Leung EH, & Wong NS (2013) Concerns for low coverage of influenza
710 vaccination in middle-aged adults. *Human vaccines & immunotherapeutics* 9(9):1989-
711 1990.
- 712 59. Centre for Health, Protection Department of Health, & The Government of the Hong
713 Kong Special Administrative Region Statistics on 2016/17 Vaccination
714 Programmes/Schemes Available at
715 http://www.chp.gov.hk/en/view_content/26734.html Accessed
- 716 60. Centers for Disease Control and Prevention National Early-Season Flu Vaccination
717 Coverage, United States, November 2016. Available at
718 <https://www.cdc.gov/flu/fluview/nifs-estimates-nov2016.htm> Accessed
- 719 61. Wu JT, *et al.* (2014) Inferring influenza infection attack rate from seroprevalence data.
720 *PLoS Pathog* 10(4):e1004054.

- 721 62. Lau EHY, Cheng CKY, Ip DKM, & Cowling BJ (2012) Situational Awareness of Influenza
722 Activity Based on Multiple Streams of Surveillance Data Using Multivariate Dynamic
723 Linear Model. *Plos One* 7(5):e38346.
- 724 63. Lau EHY, Cowling BJ, Ho LM, & Leung GM (2008) Optimizing use of multistream
725 influenza sentinel surveillance data. *Emerging infectious diseases* 14(7):1154-1157.
- 726 64. Cowling BJ, Wong IO, Ho LM, Riley S, & Leung GM (2006) Methods for monitoring
727 influenza surveillance data. *International journal of epidemiology* 35(5):1314-1321.
- 728 65. Shaman J, Karspeck A, Yang W, Tamerius J, & Lipsitch M (2013) Real-time influenza
729 forecasts during the 2012-2013 season. *Nat Commun* 4:2837.
- 730 66. Wong JY, *et al.* (2013) Infection fatality risk of the pandemic A(H1N1)2009 virus in
731 Hong Kong. *Am J Epidemiol* 177(8):834-840.
- 732 67. Yang W, Lipsitch M, & Shaman J (2015) Inference of seasonal and pandemic influenza
733 transmission dynamics. *Proc Natl Acad Sci U S A* 112(9):2723-2728.
- 734 68. Riley S, *et al.* (2011) Epidemiological characteristics of 2009 (H1N1) pandemic
735 influenza based on paired sera from a longitudinal community cohort study. *PLoS Med*
736 8(6):e1000442.
- 737 69. Tsang TK, *et al.* (2016) Interpreting Seroepidemiologic Studies of Influenza in a Context
738 of Nonbracketing Sera. *Epidemiology (Cambridge, Mass.)* 27(1):152-158.
- 739 70. Bhattacharyya S, Gesteland PH, Korgenski K, Bjornstad ON, & Adler FR (2015) Cross-
740 immunity between strains explains the dynamical pattern of paramyxoviruses. *Proc*
741 *Natl Acad Sci USA* 112(43):13396-13400.
- 742 71. Gog JR (2008) The impact of evolutionary constraints on influenza dynamics. *Vaccine*
743 26:C15-C24.

- 744 72. Nuño M, Feng Z, Martcheva M, & Castillo-Chavez C (2005) Dynamics of Two-Strain
745 Influenza with Isolation and Partial Cross-Immunity. *SIAM Journal on Applied*
746 *Mathematics* 65(3):964-982.
- 747 73. Koelle K, Khatri P, Kamradt M, & Kepler TB (2010) A two-tiered model for simulating
748 the ecological and evolutionary dynamics of rapidly evolving viruses, with an
749 application to influenza. *Journal of the Royal Society Interface* 7(50):1257-1274.
- 750 74. Arinaminpathy N, *et al.* (2012) Impact of cross-protective vaccines on epidemiological
751 and evolutionary dynamics of influenza. *Proc Natl Acad Sci USA* 109(8):3173-3177.
- 752 75. Inoue E & King A Iterated filtering: principles and practice. Available at
753 <https://kingaa.github.io/sbied/mif/mif.html> Accessed
- 754 76. Ferguson NM, Galvani AP, & Bush RM (2003) Ecological and immunological
755 determinants of influenza evolution. *Nature* 422(6930):428-433.
- 756 77. Yaari R, Katriel G, Huppert A, Axelsen JB, & Stone L (2013) Modelling seasonal
757 influenza: the role of weather and punctuated antigenic drift. *J R Soc Interface*
758 10(84):20130298.
- 759 78. Marshall A, Altman DG, Holder RL, & Royston P (2009) Combining estimates of interest
760 in prognostic modelling studies after multiple imputation: current practice and
761 guidelines. *BMC Med Res Methodol* 9:57.
- 762 79. Rubin DB (2004) *Multiple imputation for nonresponse in surveys* (John Wiley & Sons).
- 763 80. Jackson CH (2016) flexsurv: a platform for parametric survival modeling in R. *Journal*
764 *of Statistical Software* 70.

765

Table Captions:

Table 1. Estimates of key parameters. Posterior estimates from all runs and weeks are pooled to obtain the mean and full range (in parentheses).

Table 2. Estimated timing and frequency of potential punctuated antigenic changes. Dates (mm/dd/yy) of potential punctuated antigenic changes are identified based on above 15% increases in susceptibility; the standard deviations are computed based on estimates from all model-inference runs indicating punctuated antigenic changes around the same time. The time intervals between subsequent antigenic changes are estimated based on four different distributions; the best-fit estimates are shown in bold. For A(H1N1), numbers in the parentheses show results when dates during the pandemic are included.

Figure Captions:

Fig. 1. Seasonality of influenza epidemics in Hong Kong. Upper panel: annual cycles for A(H1N1) (A), A(H3N2) (B), and B (C). Color lines show infection rates for individuals years during Jan 1998 –July 2018; lighter colors show earlier years and darker colors for later years. Thick black lines show the mean excluding 2009 for the A(H1N1) pandemic. Lower panel: estimated seasonal R_0 cycles for A(H1N1) (D), A(H3N2) (E), and B (F).

Fig. 2. Estimates of weekly infection rate and population susceptibility for the three types/subtypes: A(H1N1) (A), A(H3N2) (B) and B (C). Black dots show observed incidence rates (left y-axis); the lines run through the dots show model estimates; surrounding grey areas show the 95% credible intervals (CI). Blue lines and surrounding areas show the mean and 95% CI estimates of the population susceptibility. Vertical red lines and dates show identified timing of punctuated antigenic changes.

Fig. 3. Estimates of weekly reproductive number: basic reproductive number (A) and effective reproductive number (B). Blue lines and areas show the mean and 95% CI estimates. For comparison, the observed (black dots) and estimated (black lines) incidence rates are superimposed (right y-axis).

Supplementary Material Captions: Supplemental testing and results.

Table S1. Estimated timing of punctuated antigenic changes using a cutoff of 10% increase in susceptibility, instead of 15% in Table 2.

Fig. S1. Example model fits and estimates of key parameters using a particle filter. Model fits compared to the observations are shown for A(H1N1) (A), A(H3N2) (B), and B (C). Estimates of R_0 are shown in D-F for the three influenza types/subtypes and strength of cross-immunity shown in G-L.

Fig. S2. Model validation using the first synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared

to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with punctuated antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.

Fig. S3. Model validation using the second synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with punctuated antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.

Fig. S4. Epidemics for individual types/subtypes as defined by the criteria including small epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.

Fig. S5. Epidemics for individual types/subtypes as defined by the criteria including only large epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.

Fig. S6. Distributions of residuals of incidence rate estimates. Numbers below the name of virus show the mean and 95% confidence interval in parentheses.

Fig. S7. Weekly estimates of key model parameters: infectious period for A(H1N1) (A), A(H3N2) (B), and B (C); immunity period for A(H1N1) (D), A(H3N2) (E), and B (F); and strength of cross-immunity for the six virus-pairs (G-L). Solid lines and surrounding areas show the posterior mean and 95% CI estimates and dashed lines show the prior ranges.

Fig. S8. Simulations using the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.

Fig. S9. Simulations assuming stronger cross-immunity from A(H3N2) against A(H1N1). The cross-immunity parameter c_{H1-H3} was set to 0.5 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000

individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.

Fig. S10. Simulations assuming no cross-immunity. All cross-immunity terms were set to 0 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.

Fig. S11. Epidemic and co-circulation patterns under different strengths of cross-immunity. Box and whisker plots show the distributions across 1000 simulations for each cross-immunity scenario: scenario 1 as estimated in green; scenario 2 with stronger cross-immunity from A(H3N2) against A(H1N1) in orange; and scenario 3 with no cross-immunity in grey. Horizontal thick black lines show the median; box edges show the 25th and 75th percentiles; the whiskers show the full ranges and dots show outliers. Red segments show the corresponding observations in Hong Kong.

Tables:**Table 1.** Estimates of key parameters. Posterior estimates from all runs and weeks are pooled to obtain the mean and full range (in parentheses).


Strain	Strength of cross-immunity (c_{ij})			R_0	Infectious period (days)	Immunity period (years)
	A(H1N1)	A(H3N2)	B			
A(H1N1)		0.17 (0.11, 0.23)	0.32 (0.26, 0.4)	1.44 (1.07, 1.82)	2.64 (2.15, 3.76)	3.12 (2.64, 3.98)
A(H3N2)	0.4 (0.23, 0.56)		0.24 (0.16, 0.31)	1.60 (1.32, 1.99)	3.03 (2.57, 4.30)	2.28 (1.77, 2.59)
B	0.23 (0.19, 0.32)	0.11 (0.06, 0.17)		1.43 (1.13, 1.79)	3.09 (2.15, 4.06)	3.08 (2.73, 3.48)

Table 2. Estimated timing and frequency of potential punctuated antigenic changes. Dates (mm/dd/yy) of potential punctuated antigenic changes are identified based on above 15% increases in susceptibility; the standard deviations are computed based on estimates from all model-inference runs indicating punctuated antigenic changes around the same time. The time intervals between subsequent antigenic changes are estimated based on four different distributions; the best-fit estimates are shown in bold. For A(H1N1), numbers in the parentheses show results when dates during the pandemic are included.

Strain	Timing of change		Time intervals between antigenic changes			
	Date	SD (days)	Mean (years)	SD (years)	Distribution	AIC
A(H1N1)	1/21/00	4.2	4.6 (3.7)	4.6 (3.7)	exponential	69.45
	6/11/06	0	2.9 (2.0)	0.01 (0.01)	log-norm	70.62
	1/25/09	0	4.5 (3.8)	4.1 (4.2)	gamma	71.35
	7/6/09	3.5	4.5 (3.9)	4.2 (4.7)	Weibull	71.42
	9/13/09	2.2				
	1/5/10	4				
	1/14/11	2.6				
						166.2
A(H3N2)	5/15/98	6.2	1.8	1.2	gamma	6
	1/10/99	4.2	1.8	1.1	Weibull	166.29
	1/9/00	1.9	1.4	0.01	log-norm	166.31
	6/27/00	6.3	1.8	1.8	exponential	167.15
	1/14/03	8.8				
	7/11/04	0				
	2/27/05	14.8				
	6/20/07	3.7				
	7/28/10	4				
	5/10/12	8.1				
	1/3/15	3.7				
6/8/15	5.7					
B	2/6/00	0	6.2	6.2	exponential	54.30
	1/27/02	0	3.2	0.01	log-norm	55.64
	1/6/03	7.2	6.2	6.7	Weibull	56.26
	1/13/18	0	6.2	6.4	gamma	56.29


1 **Figures:**

2 **Fig. 1.** Seasonality of influenza epidemics in Hong Kong. Upper panel: annual cycles for
3 A(H1N1) (A), A(H3N2) (B), and B (C). Color lines show infection rates for individuals years
4 during Jan 1998 –July 2018; lighter colors show earlier years and darker colors for later
5 years. Thick black lines show the mean excluding 2009 for the A(H1N1) pandemic. Lower
6 panel: estimated seasonal R_0 cycles for A(H1N1) (D), A(H3N2) (E), and B (F).




7
8
9

10 **Fig. 2.** Estimates of weekly infection rate and population susceptibility for the three
11 types/subtypes: A(H1N1) (A), A(H3N2) (B) and B (C). Black dots show observed incidence
12 rates (left y-axis); the lines run through the dots show model estimates; surrounding grey
13 areas show the 95% credible intervals (CI). Blue lines and surrounding areas show the
14 mean and 95% CI estimates of the population susceptibility. Vertical red lines and dates
15 show identified timing of punctuated antigenic changes.



16

17 **Fig. 3.** Estimates of weekly reproductive number: basic reproductive number (A) and
18 effective reproductive number (B). Blue lines and areas show the mean and 95% CI
19 estimates. For comparison, the observed (black dots) and estimated (black lines) incidence
20 rates are superimposed (right y-axis).



21
22

SI Appendix

Dynamic interactions of influenza viruses in Hong Kong during 1998-2018

Wan Yang, Eric H. Y. Lau, Benjamin J. Cowling

This supplemental document includes 1) Validation of the model-inference system using model-generated mock epidemics; 2) Simulations to test the impact of cross-immunity on long-term epidemic pattern; and supplemental table and figures.

1. Validation of the model-inference system

1.1 Method

We first tested our multi-strain SIRS model-SR-IF2 inference system using model-generated mock epidemics (i.e. synthetic data). Specifically, we tested its ability to estimate three main epidemic features of interest: 1) The population susceptibility for each virus over time, including timing of major susceptibility increase due to epochal antigenic change. For the latter, we tested three levels of magnitude—small, medium, and large change—with 10%, 15%, and 25% increase in susceptibility, respectively. 2) The strength of cross-immunity between each virus-pair. For this, we tested two combinations of heterosubtypic immunity (i.e., low H3N2→H1N1 and high H1N1→H3N2 cross-immunity for the first synthetic dataset; high H3N2→H1N1 and median H1N1→H3N2 cross-immunity for the second). and 3) The duration of immunity. Reported immunity period for influenza varied substantially, ranging from months to ~8 years (1-4). Thus, we tested prior ranges from 1 to 9 years.

To generate the mock epidemics for the above testing, we first generated 100,000 random combinations of initial conditions and model parameters except R_0 , using Latin Hypercube sampling. Weekly R_0 values were randomly sampled from a normal distribution with the mean set to the empirical estimate for that week (Fig 1 in the main text) and standard deviation set to 5% of the mean. To mimic punctuated antigenic changes, for each (sub)type, we first identified the observed major epidemic peak weeks (peak ILI+ in the upper ~75%, 60%, and 75% percentiles for the three (sub)types, respectively); for each selected peak week, we increased the susceptibility at the 8th preceding week (i.e., roughly the onset) by 15% for A(H1N1) (except for the pandemic) and A(H3N2), by 10% for B, and by 25% for the A(H1N1) pandemic (see the selected weeks in Figs S2 and S3). We then ran the multi-strain SIRS model (Eqn 1 in the main text) for each setting and selected 2 simulations that most closely resembled the observed epidemics in Hong Kong but had different levels of cross-immunity between the two A subtypes: the first simulated time series had high cross-immunity from A(H1N1) against A(H3N2) but low cross-immunity in the reverse direction; and the second had moderate cross-immunity from A(H1N1) against A(H3N2) and high cross-immunity from A(H3N2) against A(H1N1). We then added Poisson

40 random noise to the two simulated time series to mimic observational errors and used
41 these as mock data (termed synthetic 'truth') to test the model-inference system.

42
43 For each of the two synthetic truths, we performed two rounds of model-inference
44 using the same procedure and prior distributions for the Hong Kong dataset as described in
45 the main text. To evaluate the accuracy of the final posterior estimates, we computed the
46 root-mean-square-error and correlation with the 'truth'.

47 48 *1.2 Results*

49 Figures S2 and S3 show the posterior estimates of key model state variables (population
50 susceptibility for the three types/subtypes) and parameters (the basic reproductive
51 number R_0 , infectious period, immunity period and strength of cross-immunity) for the two
52 tests, respectively, compared with the true values. The relative root-mean-square-error
53 was 0.16 and the correlation was 0.83 combining all model variables/parameters from
54 both tests. These results suggest that our model-inference system and parameter
55 estimation strategy is able to accurately estimate the model state variables and parameters.
56 However, due to large fluctuations of R_0 in the synthetic datasets (e.g., Fig S2B) and the
57 collinearity between R_0 and susceptibility, the filter tended to compensate sudden
58 increases in infections (due to increases in susceptibility to mimic punctuated antigenic
59 changes) with increases in R_0 rather than susceptibility. As a result, it failed to identify
60 some of the punctuated antigenic changes, in particular, for the two A subtypes with larger
61 variances of R_0 .

62 63 **2. Simulating the impact of cross-immunity on long-term epidemic pattern**

64 *2.1 Method*

65 To test the impact of cross-immunity, we simulated epidemics under three different
66 scenarios: 1) As estimated in this study, by setting all cross-immunity terms to the
67 posterior mean estimates; 2) Stronger cross-immunity from A(H3N2) against A(H1N1), by
68 setting $c_{H1 \leftarrow H3}$ to 0.5, i.e., slightly above the mean estimate for $c_{H3 \leftarrow H1}$ (i.e. 0.4); and 3) No
69 interactions, by setting all cross-immunity terms to 0. For each simulation, we initiated the
70 multi-strain SIRS model (Eqn 1 in the main text) using the posterior estimates at Week 4
71 (i.e., after discarding the first three weeks of filter spin-off) and ran the model
72 stochastically from Jan 1998 to July 2018. Weekly values of model parameters (i.e., the
73 infectious period, immunity period, R_0 , and cross-immunity terms) not specified in the
74 above scenarios were set to the mean posterior estimates from the Hong Kong dataset.
75 Weekly susceptibilities to the three types/subtypes were simulated by the model according
76 to model-simulated infections, loss of immunity, cross-immunity, replenishment from
77 newborns, and deaths; however, to simulate the impact from antigenic innovations, we
78 reset the susceptibility to the posterior mean estimate from the Hong Kong dataset for
79 weeks identified to experience punctuated antigenic changes (Table 1). As in the model-

80 inference runs, we set the epidemic seeding (α in Eqn 1) to 0.1 per 100,000 per day for the
81 all simulations. To account for model stochasticity, we simulated each scenario for 1000
82 times.

83
84 To compute the number of epidemics over the study period, as in (5), we defined the
85 epidemic baseline, for each type/subtype, as the 40% quantile of the non-zero
86 corresponding ILI+ records over the ~20 year study period. We then identified 1) all
87 epidemics including small ones, defined as periods with ≥ 3 consecutive weeks with ILI+
88 above the baseline and at least one of the weeks with ILI+ ≥ 3 times of the baseline; and 2)
89 all large epidemics, defined as periods with ≥ 6 consecutive weeks with ILI+ above the
90 baseline and at least one of the weeks with ILI+ ≥ 6 times of the baseline. If an identified
91 epidemic lasted for >1 year, we divided it into multiple epidemics at the year division(s).
92 Based on the 1st definition, there were 17 A(H1N1), 21 A(H3N2), and 18 B epidemics,
93 respectively (Fig. S4); and based on the 2nd definition, there were 13, 19, and 14 epidemics
94 of the three types/subtypes, respectively, during Jan 1998—July 2018 (Fig. S5). We used
95 the same baselines as observed and definitions to identify and compute the numbers of
96 epidemics in the simulations and compared them to the observed.

97
98 To compare the co-circulation patterns, we categorized the weeks into 8 possible
99 co-circulation types: 1) none in circulation, i.e., none of the three types/subtypes had ILI+
100 above their baselines; 2) A(H1N1) alone, i.e., only A(H1N1) had ILI+ above its baseline; and
101 similarly, 3) A(H3N2) alone and 4) B alone; 5) A(H1N1)+A(H3N2), i.e., only A(H1N1) and
102 A(H3N2) had ILI+ above their baselines; 6) A(H1N1)+B, i.e., only A(H1N1) and B had ILI+
103 above their baselines; 7) A(H3N2)+B, i.e., only A(H3N2) and B had ILI+ above their
104 baselines; and 8) All, i.e., all three types/subtypes had ILI+ above their baselines. We then
105 computed the percentages of weeks falling in each of the 8 co-circulation types and
106 compared them to the observed.

107 108 *2.2 Results*

109 Figures 8-10 show the model-simulated epidemic trajectories compared to the
110 observations in Hong Kong. As expected, without the constraints by observations (as in a
111 model-inference system), the errors grew quickly and thus the simulated epidemics
112 deviated from the observations. However, overall, simulations with cross-immunity in
113 place were able to better reproduce the observed epidemic pattern (Figs. S8 and S9 vs. Fig.
114 S10). In particular, those simulations were able to reproduce the long periods with near-
115 zero A(H1N1) activities (e.g., 2002-2005) whereas simulations with no cross-immunity
116 (Fig. S10) overestimated the circulation of all types/subtypes, especially for A(H1N1).
117 Comparing the first two scenarios (i.e. both with cross-immunity), simulations with
118 stronger cross-immunity from A(H3N2) against A(H1N1) underestimated the circulation of
119 A(H1N1) and were only able to generate A(H1N1) epidemics following the simulated

120 punctuated antigenic changes when the susceptibility was reset (Fig. S9 vs. Fig. S8 as
121 estimated from the data).

122
123 Tally over the entire study period, the first two scenarios (i.e., with cross-immunity)
124 appeared to underestimate the total number of the epidemics (Fig. S11 A and B). However,
125 this was due to the challenge in generating clear bimodal epidemics within a year as those
126 observed in Hong Kong. For instance, there were two consecutive A(H1N1) epidemics in
127 2008; and similarly, A(H3N2) tended to cause two separate epidemics within a year, e.g.,
128 1999, 2000, 2003, and 2014. The underestimation of number of A(H1N1) epidemics was
129 severer for scenario 2 when stronger cross-immunity from A(H3N2) against A(H1N1) was
130 implemented in the model. Simulations with no cross-immunity were able to generate
131 more epidemics due to overestimation of circulation during periods without observed
132 influenza activity (Fig. S10).

133
134 Comparing the 8 co-circulation types (Fig. 11C), scenario 1 using the posterior mean
135 estimates most closely reproduced the observed pattern. In contrast, scenario 2 (i.e.,
136 stronger cross-immunity from A(H3N2) against A(H1N1)) largely underestimated the
137 frequency of A(H1N1) epidemics, whereas scenario 3 (i.e., no cross-immunity) largely
138 overestimated co-epidemics caused by multiple types/subtypes.

139
140 References:

- 141 1. Ferguson NM, Galvani AP, & Bush RM (2003) Ecological and immunological
142 determinants of influenza evolution. *Nature* 422(6930):428-433.
- 143 2. Yaari R, Katriel G, Huppert A, Axelsen JB, & Stone L (2013) Modelling seasonal
144 influenza: the role of weather and punctuated antigenic drift. *J R Soc Interface*
145 10(84):20130298.
- 146 3. Ranjeva S, *et al.* (2019) Age-specific differences in the dynamics of protective immunity
147 to influenza. *Nat Commun* 10(1):1660.
- 148 4. Kucharski AJ, *et al.* (2015) Estimating the life course of influenza A(H3N2) antibody
149 responses from cross-sectional data. *Plos Biol* 13(3):e1002082.
- 150 5. Yang W, Cowling BJ, Lau EH, & Shaman J (2015) Forecasting Influenza Epidemics in
151 Hong Kong. *PLoS Comput Biol* 11(7):e1004383.

152

Supplementary Table

Table S1. Estimated timing of punctuated antigenic changes using a cutoff of 10% increase in susceptibility, instead of 15% in Table 2.

Strain	Date	SD (days)
A(H1N1)	1/21/00	4.05
	6/11/06	0.00
	1/25/09	0.00
	7/6/09	3.50
	9/13/09	2.21
	1/4/10	6.30
	1/14/11	3.13
	A(H3N2)	1/18/98
5/15/98		6.19
1/10/99		4.31
6/13/99		12.12
1/9/00		1.94
6/27/00		5.72
1/13/03		9.46
7/11/04		0.00
2/25/05		14.53
6/20/07		3.74
7/28/10		3.83
5/10/12		8.08
1/2/15		4.21
6/6/15		8.08
B	2/6/00	0.00
	1/28/01	9.90
	1/27/02	0.00
	1/6/03	7.06
	1/13/18	0.00

Supplementary figures

Fig. S1. Example model fits and estimates of key parameters using a particle filter. Model fits compared to the observations are shown for A(H1N1) (A), A(H3N2) (B), and B (C). Estimates of R_0 are shown in D-F for the three influenza types/subtypes and strength of cross-immunity shown in G-L.




Fig. S2. Model validation using the first synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with epochal antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.




Fig. S3. Model validation using the second synthetic dataset. Posterior estimates for the incidence rate and population susceptibility (A), basic reproductive number R_0 (B), infectious period (C), immunity period (D), and strength of cross-immunity (E), compared to the true values. In (A) and (B), dots show the true incidence rates (in black; right y-axis), susceptibility (in blue; left y-axis), and R_0 (in blue; left y-axis); the lines and surrounding areas show the mean and 95% credible interval (CI) estimates. In (A), vertical dashed black lines show the true weeks with epochal antigenic changes and red lines show model-estimates. In (C)-(E), red stars show true parameter values; box plots show the median, 75%, and 95% CIs of posterior estimates by the model-inference system; orange dashed lines show the prior ranges tested.




Fig. S4. Epidemics for individual types/subtypes as defined by the criteria including small epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.




Fig. S5. Epidemics for individual types/subtypes as defined by the criteria including only large epidemics: (A) A(H1N1), (B) A(H3N2), and (C) B. Black lines are ILI+ observations; red horizontal lines are baselines; blue vertical lines are the identified onsets; cyan vertical lines are identified endings; grey vertical lines are year divisions.




Fig. S6. Distributions of residuals of incidence rate estimates. Numbers below the name of virus show the mean and 95% confidence interval in parentheses.




Fig. S7. Weekly estimates of key model parameters: infectious period for A(H1N1) (A), A(H3N2) (B), and B (C); immunity period for A(H1N1) (D), A(H3N2) (E), and B (F); and strength of cross-immunity for the six virus-pairs (G-L). Solid lines and surrounding areas show the posterior mean and 95% CI estimates and dashed lines show the prior ranges.




Fig. S8. Simulations using the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.




Fig. S9. Simulations assuming stronger cross-immunity from A(H3N2) against A(H1N1). The cross-immunity parameter $c_{H1 \leftarrow H3}$ was set to 0.5 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.




Fig. S10. Simulations assuming no cross-immunity. All cross-immunity terms were set to 0 and other parameters set to the posterior mean estimates. Colored lines show simulated weekly infection rates from 1000 individual stochastic model runs (A(H1N1) in orange, A(H3N2) in red, and B in green); dashed black lines show the weekly mean infection rates across 1000 simulations and solid black lines show the weekly observations for comparison.




Fig. S11. Epidemic and co-circulation patterns under different strengths of cross-immunity. Box and whisker plots show the distributions across 1000 simulations for each cross-immunity scenario: scenario 1 as estimated in green; scenario 2 with stronger cross-immunity from A(H3N2) against A(H1N1) in orange; and scenario 3 with no cross-immunity in grey. Horizontal thick black lines show the median; box edges show the 25th and 75th percentiles; the whiskers show the full ranges and dots show outliers. Red segments show the corresponding observations in Hong Kong.

